Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more
Medigen Vaccine Biologics (6547) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.003x
Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of -0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-9.07 Million) by net assets (NT$3.61 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medigen Vaccine Biologics - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boston Omaha Corp
NYSE:BOC
|
0.009x |
|
Meitav Trade Inv Ltd
TA:MTRD
|
N/A |
|
Shuifa Energas Gas Co Ltd
SHG:603318
|
-0.019x |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
-0.007x |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.423x |
|
Akebia Therapeutics Inc
F:AX9
|
0.676x |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
0.073x |
|
Atlanticus Holdings Corporation
NASDAQ:ATLC
|
0.172x |
Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$3.85 Billion | NT$40.75 Million | 0.011x | +108.52% |
| 2023-12-31 | NT$3.85 Billion | NT$-477.75 Million | -0.124x | +43.27% |
| 2022-12-31 | NT$5.03 Billion | NT$-1.10 Billion | -0.219x | -276.53% |
| 2021-12-31 | NT$4.68 Billion | NT$579.89 Million | 0.124x | +166.03% |
| 2020-12-31 | NT$3.14 Billion | NT$-589.97 Million | -0.188x | +44.52% |
| 2019-12-31 | NT$1.37 Billion | NT$-462.65 Million | -0.338x | -53.14% |
| 2018-12-31 | NT$1.61 Billion | NT$-356.33 Million | -0.221x | -54.92% |
| 2017-12-31 | NT$1.52 Billion | NT$-217.03 Million | -0.143x | -28.34% |
| 2016-12-31 | NT$1.47 Billion | NT$-163.37 Million | -0.111x | -169.10% |
| 2015-12-31 | NT$1.34 Billion | NT$216.26 Million | 0.161x | +133.76% |
| 2014-12-31 | NT$1.08 Billion | NT$-513.98 Million | -0.476x | -201.54% |
| 2013-12-31 | NT$457.94 Million | NT$-72.36 Million | -0.158x | -269.62% |
| 2012-12-31 | NT$128.00 Million | NT$-5.47 Million | -0.043x | -- |